5/23
09:22 am
lexx
Lexaria Awards Contract For Third GLP-1 Human Pilot Study [Yahoo! Finance]
Low
Report
Lexaria Awards Contract For Third GLP-1 Human Pilot Study [Yahoo! Finance]
5/23
09:05 am
lexx
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
Low
Report
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
5/21
09:41 am
lexx
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy [Yahoo! Finance]
Low
Report
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy [Yahoo! Finance]
5/21
09:20 am
lexx
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
Medium
Report
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
5/17
09:22 am
lexx
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study [Yahoo! Finance]
Low
Report
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study [Yahoo! Finance]
5/17
09:10 am
lexx
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
Medium
Report
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
5/9
10:50 am
lexx
Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation [Yahoo! Finance]
Medium
Report
Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation [Yahoo! Finance]
5/8
09:19 am
lexx
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study [Yahoo! Finance]
Low
Report
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study [Yahoo! Finance]
5/8
09:10 am
lexx
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
Medium
Report
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
5/6
09:05 am
lexx
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
Low
Report
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
4/30
03:53 pm
lexx
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance [Yahoo! Finance]
Low
Report
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance [Yahoo! Finance]
4/30
03:40 pm
lexx
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
Medium
Report
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
4/16
09:23 am
lexx
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study [Yahoo! Finance]
High
Report
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study [Yahoo! Finance]
4/16
09:10 am
lexx
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Medium
Report
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
4/2
09:29 am
lexx
Lexaria Awarded New Patents [Yahoo! Finance]
Low
Report
Lexaria Awarded New Patents [Yahoo! Finance]
4/2
09:00 am
lexx
Lexaria Awarded New Patents
Low
Report
Lexaria Awarded New Patents
3/21
09:29 am
lexx
Lexaria to Present at The LD Micro Invitational XIV [Yahoo! Finance]
High
Report
Lexaria to Present at The LD Micro Invitational XIV [Yahoo! Finance]
3/14
09:26 am
lexx
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer [Yahoo! Finance]
3/14
09:20 am
lexx
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
High
Report
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
3/7
09:16 am
lexx
Lexaria Awards Contract For Next GLP-1 Human Pilot Study [Yahoo! Finance]
Low
Report
Lexaria Awards Contract For Next GLP-1 Human Pilot Study [Yahoo! Finance]
3/7
09:05 am
lexx
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Medium
Report
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
3/5
12:59 pm
lexx
Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes [Seeking Alpha]
Medium
Report
Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes [Seeking Alpha]
3/5
11:43 am
lexx
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its price target raised by analysts at Maxim Group from $3.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its price target raised by analysts at Maxim Group from $3.00 to $12.00. They now have a "buy" rating on the stock.
3/5
09:17 am
lexx
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 [Yahoo! Finance]
Medium
Report
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 [Yahoo! Finance]
3/5
09:05 am
lexx
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Medium
Report
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1